Navigation Links
Pfenex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the Use of Pfenex Expression Technology™
Date:2/15/2011

SAN DIEGO and INGELHEIM, Germany, Feb. 15, 2011 /PRNewswire/ -- Pfenex Inc., an industry leader in protein expression through the Pfenex Expression Technology™ platform and Boehringer Ingelheim International GmbH, a leading pharmaceutical company and global leader in biopharmaceutical contract development and manufacture, announced today that they have entered into a strategic agreement. It provides Boehringer Ingelheim with non-exclusive access to the Pfenex Expression Technology. Under the terms of the multi-year agreement, Pfenex Inc. will engineer production strains and processes for Boehringer Ingelheim's proprietary molecules, and molecules from Boehringer Ingelheim's contract manufacturing customers. This collaboration provides Boehringer Ingelheim and their customers with access to an industry-leading expression platform to enable preclinical and clinical development to progress much more quickly and efficiently.

"We are very pleased to have established this agreement with Boehringer Ingelheim," said Dr Bertrand Liang, CEO of Pfenex Inc. "This partnership combines a cutting edge expression technology with the leading innovative pharmaceutical company and contract services provider, facilitating the speed and reliability with which important new drugs can be brought to patients."

"This collaboration extends our contract manufacturing service portfolio by an additional high expression system and is a further step in our strategy to offer customers leading technologies," stated Simon Sturge, Corporate SVP of the Biopharmaceuticals Division at Boehringer Ingelheim. "The Pfenex Expression Technology™ delivers excellent expression rates, and we are looking forward to realizing customer projects with this technology."

About Pfenex Inc.

Pfenex Inc. is a protein production company leveraging the unique and powerful Pfenex Expression Technology™ platform based on the microorganism, Pseudomonas fluorescens, for the production of research proteins, reagent proteins, biosimilars and innovator biopharmaceuticals. For more information please visit www.pfenex.com

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees. Since it was founded in 1885, the family-owned company has been committed for 125 years to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2009, Boehringer Ingelheim posted net sales of 12.7 billion euro while spending 21% of net sales in its largest business segment Prescription Medicines on research and development.

For more information please visit www.boehringer-ingelheim.com.

Today, Boehringer Ingelheim is one of the world's leading companies for contract development and manufacture of biopharmaceuticals. All types of services from mammalian cell line or microbial strain development to final drug production can be delivered within a one-stop-shop concept. Boehringer Ingelheim delivers services for pre-clinical development up to global market supply with a strong commitment to its customers at its manufacturing facilities for mammalian cell culture and microbial fermentation. Boehringer Ingelheim has brought 18 molecules to market and has  many  years  of  experience  in  multiple  molecule  classes  such  as monoclonal antibodies, recombinant proteins, interferons, enzymes, fusion molecules and plasmid DNA. Furthermore, high-titer platform technologies for new antibody mimetic formats such as scaffold proteins and antibody fragments are available for the manufacture of customer products.

For more information contact: bio-cmo@boehringer-ingelheim.com or www.biopharma-cmo.com


'/>"/>
SOURCE Pfenex Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pfenex Grants Exclusive License to Merck & Co., Inc. for the Production of Proteins for Undisclosed Vaccine Program
2. Pfenex Inc. Awarded Contract With the United States Federal Government Potentially Totaling Up to $18.8 Million to Develop a Robust Pfenex Expression Technology Based Process for the Production of Bulk Recombinant Protective Antigen (rPA) From Anthr
3. Pfenex Inc. Establishes Reagent Protein Distribution Agreement With Cedarlane Corporation
4. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
5. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
6. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
7. Boehringer Ingelheim Unveils Diabetes Pipeline
8. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
9. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
10. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
11. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... July 10, 2017  BDI Group subsidiary Pathway ... support services organization serving specialty pharmacies, home infusion ... of four significant, value-added member programs designed to ... manage reimbursement and improve access and affordability for ... Pathway ...
(Date:7/5/2017)... Wolfmet 3D  printed tungsten collimator manufactured by M&I Materials ... combine to progress molecular radiotherapy imaging. In molecular ... to accurately quantify the radiation absorbed by those patients undergoing ... of this radiotherapy treatment has been available — that is, ... ...
(Date:7/1/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced ... broadcast live over the Internet on Thursday, July 27, 2017, ... quarterly results will be made available at 7:30 a.m. Eastern ... live audio webcast can be accessed via Zimmer Biomet,s Investor ... for replay following the conference call. ...
Breaking Medicine Technology:
(Date:7/18/2017)... ... 18, 2017 , ... CannaKids, a California Cooperative Cooperation that specializes in the ... the WORLDZ Summit, taking place in Hollywood from July 31-August 1, the Company’s ... cannabis for both pediatric and adult patients, and how the path has led her ...
(Date:7/18/2017)... ... 2017 , ... Doctors on Liens, the leading network of ... who offer the most effective and efficient care on a lien basis. Doctors ... each patient receives prompt and courteous service, same or next day appointments, and ...
(Date:7/18/2017)... ... July 19, 2017 , ... USHEALTH Group, ... Responsibility Initiative in the prestigious CEO World Awards®. The coveted annual CEO ... products and services, CEO case studies, corporate social responsibility, and milestones from every ...
(Date:7/17/2017)... ... ... McGraw Family Pledges $3 Million for New Learning Center at Norwalk Hospital, New ... NORWALK, Connecticut – July 17, 2017 – The McGraw family, founders of global multimedia ... up to $3 million in a challenge gift to establish the new McGraw Family ...
(Date:7/17/2017)... ... July 17, 2017 , ... Western University of Health Sciences ... Higher Education for the sixth consecutive year, and also made the Honor Roll ... and Lebanon, Oregon, was recognized in seven categories: Collaborative Governance, Compensation & Benefits, ...
Breaking Medicine News(10 mins):